enrollment

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

News

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food ... Read more

October 8, 2020October 8, 2020

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

News

Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond ... Read more

December 16, 2019December 16, 2019

Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada

News

Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number of men enrolled to more than 200 in the validation study of ClarityDX Prostate, a new ... Read more

October 10, 2018October 10, 2018

Phase 3 Study Weighs Benefits of Standard Drugs Plus Surgery or Radiation Therapy

News

The first patients have been enrolled in a Phase 3 clinical trial to evaluate if combining either prostate removal surgery or radiation therapy with standard systemic therapy delays cancer progression and improves survival of patients ... Read more

June 27, 2018June 27, 2018

Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients

News

Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The ... Read more